Literature DB >> 16646673

No polarization of type 1 or type 2 precursor dendritic cells in peripheral blood stem cell collections of non-hodgkin's lymphoma patients mobilized with cyclophosphamide plus G-CSF, GM-CSF, or GM-CSF followed by G-CSF.

Yair Gazitt1, Cagla Akay, Charles Thomas.   

Abstract

Dendritic cells (DCs) are the most efficient antigen-presenting cells and play a role in immune reconstitution after autologous transplantation. Recent reports suggest that mobilization with granulocyte colony-stimulating factor (G-CSF) containing regimens polarizes DCs into pDC2, which could potentially result with increased Th2 response and decreased graft-versus-host disease (GVHD) in allogeneic transplantation and with decreased cytotoxic Th1 response and graft versus tumor effect, which in autologous transplantation could translate into increased relapse rate. Previously, we have shown that non-Hodgkin's lymphoma (NHL) patients receiving cyclophosphamide (CTX) plus granulocyte- macrophage (GM)-CSF, G-CSF or GM-CSF followed by G-CSF for stem cell collection, mobilize up to five-fold more mature CD80(+) DCs compared to CTX plus G-CSF mobilized patients. Here, we analyzed samples from the same study for the number of pDC1 and pDC2 subsets in blood and apheresis products obtained from these patients. Samples from 29 patients were collected. Patients mobilized with CTX plus G-CSF collected a mean of 1.2 +/- 0.4 x 10(6) pDC1/kg per day and 2.2 +/- 1 x 10(6) pDC2/kg per day, whereas patients mobilized with CTX plus GM-CSF collected a mean of 1.1 +/- 0.5 x 10(6) pDC1 and 1.5 +/- 0.9 x 10(6) pDC2/kg per day. Patients mobilized with CTX plus GM-CSF followed by G-CSF collected 2.5 +/- 1.1 x 10(6) pDC1 and 2 +/- 0.5 x 106 pDC2/kg per day, with significantly higher levels of pDC1 +/- pDC2 cells. No significant difference was observed in pDC1/pDC2 ratio between the three mobilization arms. Patients mobilized with the GM-CSFcontaining regimen had a higher probability for survival compared to patients receiving G-CSF alone (median of 55 months vs. 15 months; p = 0.02). These results support the hypothesis that higher levels of DCs in the graft might be associated with prolonged survival of autotransplanted NHL patients. Further similar studies are merited in a larger population of NHL patients.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16646673     DOI: 10.1089/scd.2006.15.269

Source DB:  PubMed          Journal:  Stem Cells Dev        ISSN: 1547-3287            Impact factor:   3.272


  9 in total

1.  Cyclophosphamide induces dynamic alterations in the host microenvironments resulting in a Flt3 ligand-dependent expansion of dendritic cells.

Authors:  Mohamed L Salem; Amir A Al-Khami; Sabry A El-Naggar; C Marcela Díaz-Montero; Yian Chen; David J Cole
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

2.  Effects of pegylated G-CSF on immune cell number and function in patients with gynecological malignancies.

Authors:  Giuseppina Bonanno; Annabella Procoli; Andrea Mariotti; Maria Corallo; Alessandro Perillo; Silvio Danese; Raimondo De Cristofaro; Giovanni Scambia; Sergio Rutella
Journal:  J Transl Med       Date:  2010-11-09       Impact factor: 5.531

Review 3.  Dendritic cell recovery post-lymphodepletion: a potential mechanism for anti-cancer adoptive T cell therapy and vaccination.

Authors:  Mohamed Labib Salem; David J Cole
Journal:  Cancer Immunol Immunother       Date:  2009-11-18       Impact factor: 6.968

4.  Recovery from cyclophosphamide-induced lymphopenia results in expansion of immature dendritic cells which can mediate enhanced prime-boost vaccination antitumor responses in vivo when stimulated with the TLR3 agonist poly(I:C).

Authors:  Mohamed L Salem; C Marcela Díaz-Montero; Amir A Al-Khami; Sabry A El-Naggar; Osama Naga; Alberto J Montero; Ahmed Khafagy; David J Cole
Journal:  J Immunol       Date:  2009-02-15       Impact factor: 5.422

5.  Cyclophosphamide induces bone marrow to yield higher numbers of precursor dendritic cells in vitro capable of functional antigen presentation to T cells in vivo.

Authors:  Mohamed L Salem; Sabry A El-Naggar; David J Cole
Journal:  Cell Immunol       Date:  2009-12-05       Impact factor: 4.868

6.  A randomized study comparing chemotherapy followed by G-CSF alone or in combination with GM-CSF for mobilization of peripheral blood stem cells in patients with non-Hodgkin's lymphomas.

Authors:  Chitra Hosing; Mark F Munsell; James M Reuben; Uday Popat; Bang-Ning Lee; Hui Gao; Martin Körbling; Elizabeth J Shpall; Partow Kebriaei; Amin Alousi; Marcos De Lima; John McMannis; Muzaffar Qazilbash; Paolo Anderlini; Sergio Giralt; Richard E Champlin; Issa Khouri
Journal:  J Blood Med       Date:  2010-04-14

7.  Clinical uses of GM-CSF, a critical appraisal and update.

Authors:  Martha Arellano; Sagar Lonial
Journal:  Biologics       Date:  2008-03

8.  Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography.

Authors:  Chengzhong Fan; Miguel Hernandez-Pampaloni; Mohamed Houseni; Wichana Chamroonrat; Sandip Basu; Rakesh Kumar; Simin Dadparvar; Drew A Torigian; Abass Alavi
Journal:  Mol Imaging Biol       Date:  2007 Sep-Oct       Impact factor: 3.484

Review 9.  Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin's lymphoma and multiple myeloma.

Authors:  Louis M Pelus; Sherif S Farag
Journal:  Stem Cells Cloning       Date:  2011-02-27
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.